Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Summary

Propanc Biopharma is positioning its PRP drug candidate's EMT-reversal mechanism as a complementary therapeutic approach to emerging RAS inhibitor programs from Revolution Medicines and Erasca.